MANGOCEUTICALS, INC. Files 8-K: Equity Sales & Officer Changes
Ticker: MGRX · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $15,000, $50,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-sale, officer-changes, director-changes, compensation
TL;DR
MANGOCEUTICALS sold unregistered equity and changed officers on 6/3.
AI Summary
On June 3, 2024, MANGOCEUTICALS, INC. reported on the unregistered sale of equity securities and changes in its board and officer composition. The company also disclosed compensatory arrangements for certain officers. Specific details regarding the equity sale and compensation were not fully elaborated in the provided text.
Why It Matters
This filing indicates potential dilution from equity sales and changes in corporate leadership, which could impact investor confidence and strategic direction.
Risk Assessment
Risk Level: medium — Unregistered equity sales can signal financial distress or dilution, while changes in officers can indicate internal shifts or strategic realignments.
Key Numbers
- 001-41615 — SEC File Number (Identifier for MANGOCEUTICALS, INC.)
- 87-3841292 — IRS Employer Identification No. (Tax identification for MANGOCEUTICALS, INC.)
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- June 3, 2024 (date) — Date of Earliest Event Reported
- Texas (location) — State of Incorporation
- Dallas (location) — Principal Executive Offices City
- 75248 (postal_code) — Principal Executive Offices Zip Code
FAQ
What type of equity securities were sold unregistered?
The filing indicates an 'Unregistered Sales of Equity Securities' but does not specify the type of securities in the provided text.
Who are the specific officers or directors whose departure or election is being reported?
The filing mentions 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' but does not name the individuals in the provided text.
What are the details of the compensatory arrangements for certain officers?
The filing notes 'Compensatory Arrangements of Certain Officers' but does not provide specific details in the excerpt.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is June 3, 2024.
What is the principal executive office address for MANGOCEUTICALS, INC.?
The principal executive office is located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248.
Filing Stats: 796 words · 3 min read · ~3 pages · Grade level 13.9 · Accepted 2024-06-05 17:15:26
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MGRX The Nasdaq
- $15,000 — t to the terms of the agreement include $15,000 in cash per month, and $50,000 of share
- $50,000 — include $15,000 in cash per month, and $50,000 of shares of common stock due after (a)
Filing Documents
- form8-k.htm (8-K) — 40KB
- 0001493152-24-022808.txt ( ) — 213KB
- mgrx-20240603.xsd (EX-101.SCH) — 3KB
- mgrx-20240603_lab.xml (EX-101.LAB) — 33KB
- mgrx-20240603_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: June 5, 2024 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer